Preoperative Stereotactic Radiosurgery for Brain Metastases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-04

Study Completion Date

2025-11-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

STEP is a French multicentre, prospective, non-randomized, phase II study designed to assess 6-months local control after pre-operative stereotactic radiosurgery (SRS) for patients with brain metastases

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal

NCT03696680

Hemorrhagic Brain Metastases

RECRUITING PHASE2

Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma

NCT01507506

Glioblastoma

TERMINATED PHASE3

Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery

NCT01372774

Radiation Toxicity Cognitive/Functional Effects Metastatic Cancer +2 more

COMPLETED PHASE3

Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease

NCT04114981

Metastatic Malignant Neoplasm in the Brain

ACTIVE_NOT_RECRUITING PHASE3

Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors

NCT03750227

Malignant Solid Neoplasm Metastatic Malignant Neoplasm in the Brain

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental arm (all patients)

Patients will receive preoperative hypofractionated stereotactic radiosurgery (SRS).

According to the association of french-speaking neuro-oncologists (ANOCEF) recommendations, total dose and fractionation will be 33 Gy in 3 fractions at the isocenter, 23.1 Gy in envelope (70% isodose), i.e. 30 Gy in growth tumor volume (GTV) envelope.) Surgery will take place within 3 days of the preoperative SRS.

Group Type EXPERIMENTAL

Preoperative SRS

Intervention Type PROCEDURE

Patient will be treat with preoperative SRS and then surgery for brain metastases is realized within 3 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Preoperative SRS

Patient will be treat with preoperative SRS and then surgery for brain metastases is realized within 3 days.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≤ 4 distinct brain metastases, one with surgical indication
* Diagnosis of primary histologically proven breast, digestive or non-small cells lung cancer
* ≤ 5 cm larger diameter
* Karnofsky performance status ≥ 70
* No contraindication for MRI
* Possibility for the patient to be treat with both surgery and stereotactic radiotherapy
* ≥ 18 years old
* Estimated overall survival ≥ 6 months according to diagnosis specific - graded prognostic assessment (DS GPA)
* Written inform consent signed
* Affiliation to the French social security system
* For women of childbearing age including those on luteinizing hormone-releasing hormone (LH-RH) agonists for ovarian suppression: inclusion negative serum pregnancy test (≤ 7 days prior to the start of preoperative stereotactic radiosurgery (SRS).

Exclusion Criteria

* Lymphoma, leukaemia, multiple myeloma, germinal tumours or cerebral primary cancer
* Metastases from small-cells lung cancer, kidney cancer, melanoma or sarcoma
* Mass effect with deflection ≥ 5 mm from median line or hydrocephaly or compression 4th ventricle, patient neurologically unstable, need for emergency decompressive surgery
* \> 4 brain metastases
* Contraindication to anaesthesia, MRI or gadolinium injection
* Proximity of the tumour with organs at risk which do not allow the prescribed dose to be reached in the envelope
* Pregnant or breastfeeding woman
* Anti vascular endothelial growth factor (VEGF) within 6 weeks before treatment
* Documented leptomeningeal injury
* History of irradiation of the encephalon in toto
* History of stereotactic radiotherapy on metastasis to be operated on
* Non-candidate patient for surgery
* Surgical delay \> 3 days compared to stereotactic radiotherapy
* Estimated survival \< 6 months by DS GPA
* Patient under guardianship or curators
* Psychological disorder (cognitive disorders, mental alertness, etc.) or social (deprivation of liberty by judicial or administrative decision) or geographical reasons that may compromise medical monitoring of the trial or compliance with treatment
* Woman of childbearing age without effective contraception
* Patient participating in another intervention study within 4 weeks prior to inclusion

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No